Lantheus Holdings, Inc. SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense
Lantheus Holdings, Inc. (LNTH) reported SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense of $105.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Valuation and Qualifying Accounts
us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense · last filed 2026-08-06
- Lantheus Holdings, Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for the quarter ending 2026-06-30 was $55.47M.
- Lantheus Holdings, Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for the quarter ending 2026-03-31 was $49.85M.
- Lantheus Holdings, Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2025 was $167.63M, a 163.96% increase from fiscal 2024.
- Lantheus Holdings, Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2024 was $63.50M, a 99.35% increase from fiscal 2023.
- Lantheus Holdings, Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2023 was $31.86M, a 19.38% increase from fiscal 2022.
- Lantheus Holdings, Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2022 was $26.68M, a 3.53% increase from fiscal 2021.
| Period end | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 3 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 6 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 12 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 12 month as first filed |
|---|---|---|---|---|
| 2026-06-30 | $55.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $105.31M 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $49.85M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $167.63M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $63.50M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $31.86M 10-K · filed 2026-02-26 | $32.31M 10-K · filed 2024-02-22 | ||
| 2022-12-31 | $26.68M 10-K · filed 2024-02-22 | |||
| 2021-12-31 | $25.77M 10-K · filed 2023-02-23 | |||
| 2020-12-31 | $19.68M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |